摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[6(2-Fluoroethylamino)-3-pyridyl]-N"-cyano-n'-(1-phenylcyclobutyl)guanidine | 170793-40-5

中文名称
——
中文别名
——
英文名称
N-[6(2-Fluoroethylamino)-3-pyridyl]-N"-cyano-n'-(1-phenylcyclobutyl)guanidine
英文别名
1-Cyano-3-[6-(2-fluoroethylamino)pyridin-3-yl]-2-(1-phenylcyclobutyl)guanidine
N-[6(2-Fluoroethylamino)-3-pyridyl]-N"-cyano-n'-(1-phenylcyclobutyl)guanidine化学式
CAS
170793-40-5
化学式
C19H21FN6
mdl
——
分子量
352.414
InChiKey
JHHJVGYJHLQCFD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    26
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    85.1
  • 氢给体数:
    3
  • 氢受体数:
    5

文献信息

  • CYANOGUANIDINES AS K-CHANNEL BLOCKERS
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:EP0741708A1
    公开(公告)日:1996-11-13
  • US5668157A
    申请人:——
    公开号:US5668157A
    公开(公告)日:1997-09-16
  • [EN] CYANOGUANIDINES AS K-CHANNEL BLOCKERS<br/>[FR] CYANOGUANIDINES UTILISEES COMME AGENTS BLOQUANTS DES CANAUX K
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:WO1995020579A1
    公开(公告)日:1995-08-03
    (EN) Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R1 is hydrogen or methyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl C3-C5 cycloalkyl, C3-C5 cycloalkenyl, hydroxymethyl, methoxy C1-C5 alkyl, or R1 and R2 are combined to form a C3-C6 carboxyclic ring; R3 and R4 are each independently selected to be hydrogen, C1-C4 alkyl, F, Cl, Br, I or CF3; R5 is hydrogen, F or Cl; R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyl, NHC(O)C1-C3 alkyl, F, Cl, Br, C1-C3 alkyl, NH(CH2)mF, 1-imidazolyl, NHOC1-C3 alkyl, NHOH, NHSO2C1-C3 alkyl, SH, SC1-C3 alkyl, NHC(O)OC1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2 or amino acid amide; R7 is C1-C7 alkyl, NH2, NHC1-C3 alkyl, N(C1-C3 alkyl)2, CF3, F, Cl, Br, I, OC1-C3 alkyl, OH, COOH, C(O)OC1-C3 alkyl, C(O)NH2, C(O)NHC1-C3 alkyl, C(O)C1-C3 alkyl, C(O)N(C1-C3 alkyl)2, SO2NH2, SO2NHC1-C3 alkyl, CN, SO2N(C1-C3 alkyl)2, NHC(O)C1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHC(O)N(C1-C3 alkyl)2, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2, SH, SC1-C3 alkyl, NO2, SO2C1-C3 alkyl, NHC(O)OC1-C3 alkyl, amino acid amide or hydrogen; R8 is hydrogen, C1-C6 alkyl, NH2, NHC1-C3 alkyl, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyl or OH; and where m is 2 or 3 and n is 0 or 1 (except for those compounds where R8 is hydrogen and R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyl, NHC(O)C1-C3 alkyl, Cl or Br). The compounds of Formula (I) are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.(FR) L'invention se rapporte à des composés de cyanoguanidine de la formule (I) et à leurs sels d'addition acides pharmaceutiquement acceptables, formule dans laquelle R1 représente hydrogène or méthyle; R2 représente alkyle C1-C6, alcényle C2-C6, alkynyle C2-C6, cycloalkyle C3-C5, cycloalcényle C3-C5, hydroxyméthyle, méthoxy C1-C5 alkyle, ou bien R1 et R2 sont combinés pour former un cycle carbocyclique C3-C6; R3 et R4 sont chacun, indépendamment, sélectionnés parmi hydrogène, alkyle C1-C4, F, Cl, Br, I ou CF3; R5 représente hydrogène, F ou Cl; R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyle, NHC(O)C1-C3 alkyle, F, Cl, Br, alkyle C1-C3 , NH(CH2)mF, 1-imidazolyle, NHOC1-C3 alkyle, NHOH, NHSO2C1-C3 alkyle, SH, SC1-C3 alkyle, NHC(O)OC1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2 ou un amide d'acide aminé; R7 représente alkyle C1-C7, NH2, NHC1-C3 alkyle, N(alkyle C1-C3)2, CF3, F, Cl, Br, I, OC1-C3 alkyle, OH, COOH, C(O)OC1-C3 alkyle, C(O)NH2, C(O)NHC1-C3 alkyle, C(O)C1-C3 alkyle, C(O)N(alkyle C1-C3)2, SO2NH2, SO2NHC1-C3 alkyle, CN, SO2N(alkyle C1-C3)2, NHC(O)C1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHC(O)N(alkyle C1-C3)2, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2, SH, SC1-C3 alkyle, NO2, SO2C1-C3 alkyle, NHC(O)OC1-C3 alkyle, un amide d'acide aminé ou hydrogène; R8 représente hydrogène, alkyle C1-C6, NH2, NHC1-C3 alkyle, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyle ou OH; et où m vaut 2 ou 3 et n vaut 0 ou 1 (excepté pour les composés où R8 représente hydrogène et R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyle, NHC(O)C1-C3 alkyle, Cl ou Br). Les composés de la formule (I) sont des agents bloquants des canaux de potassium utiles dans le traitement de troubles cardiovasculaires, tels que l'insuffisance cardiaque congestive et l'hypertension, et agissent également comme diurétiques.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)